Earlier roles on record: CEO and Board Member at Personalis, Inc. (PSNL) until December 31, 2022. Personalis, Inc. reported in an 8-K filed December 14, 2022 that John West retired as member of the board of directors, effective December 31, 2022. Personalis, Inc. reported in an 8-K filed December 14, 2022 that John West retired as Chief Executive Officer, effective December 31, 2022. The proxy statement of Personalis, Inc. reports total compensation of $5,615,508 for John West in fiscal 2022, including a base salary of $618,000. Disclosed compensation is on record for 5 fiscal years. John West has spoken on 11 earnings calls across 1 company, most recently for Personalis, Inc. on November 2, 2022. The companies whose calls John West spoke on are classified in the Healthcare sector.
“On December 9, 2022, John West, co-founder, Chief Executive Officer and member of the board of directors (the "Board") of Personalis, Inc. (the "Company") notified the Company of his decision to retire as Chief Executive Officer and as a director of the Company, effective as of December 31, 2022.”
Personalis, Inc. Form 8-K, filed December 14, 2022
· Read the filing
“On December 9, 2022, John West, co-founder, Chief Executive Officer and member of the board of directors (the "Board") of Personalis, Inc. (the "Company") notified the Company of his decision to retire as Chief Executive Officer and as a director of the Company, effective as of December 31, 2022.”
Personalis, Inc. Form 8-K, filed December 14, 2022
· Read the filing
John West on recent calls
“In Q3, all of our revenue came from our oncology business, which was up 73% over the same period from the prior year. Going forward, we expect the centerpiece of our oncology business to be our MRD test, NeXT Personal.”
“I'm pleased with our progress this quarter as we drove growth from our oncology business by 74% over the same period last year. This reflects increasing demand for our highly differentiated and comprehensive cancer tests.”
“Personalis continues to make progress on our strategic priorities with the aim of becoming a leading provider of the most comprehensive and actionable cancer genomic tests, and ultimately, enabling a new standard of oncology care that could help patients live better and longer lives.”
“Personalis continues to grow, particularly our oncology business. In Q4, revenue from our oncology business was $15.4 million and grew 102% over the same period of the prior year.”
“Personalis continues to grow, driven particularly by our oncology business. In Q3, revenue from our oncology business grew 50% over the same period of the prior year.”
